1 BTC
=
- USD
Vincerx Pharma, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
Market Statistics
Trading Metrics
How to Buy VINC
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy VINC
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesUS stock futures were volatile ahead of the market open, with experts advising investors to focus on capital preservation due to high uncertainty. The article discusses concerns over liquidity issues in the US banking system and the impact of tariffs on the markets.
Vincerx Pharma has entered into a non-binding letter of intent to merge with QumulusAI, a private AI infrastructure company. The proposed transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx.
Vincerx Pharma has terminated its reverse merger term sheet and is now evaluating strategic alternatives, including out-licensing, mergers and acquisitions, asset sales, and winding down operations.
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties to shareholders in several merger and acquisition transactions, including Getty Images Holdings, Inc., Colombier Acquisition Corp. II, Vincerx Pharma, Inc., and NeueHealth, Inc.
Kuehn Law, a shareholder litigation law firm, is investigating potential claims related to proposed mergers involving Vincerx Pharma, NeueHealth, Getty Images Holdings, and Colombier Acquisition Corp, II. The firm is examining whether the boards of these companies acted to maximize shareholder value, failed to disclose material information, and conducted a fair process.
